CHO Pharma (ROCO:6586) Debt-to-Asset : 0.01 (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is CHO Pharma Debt-to-Asset?

CHO Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$14.31 Mil. CHO Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$14.59 Mil. CHO Pharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was NT$2,881.29 Mil. CHO Pharma's debt to asset for the quarter that ended in Dec. 2024 was 0.01.

CHO Pharma Debt-to-Asset Historical Data

The historical data trend for CHO Pharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CHO Pharma Debt-to-Asset Chart

CHO Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.02

0.01

CHO Pharma Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.01	-	-	0.01	0.01

Competitive Comparison of CHO Pharma's Debt-to-Asset

For the Biotechnology subindustry, CHO Pharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CHO Pharma's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CHO Pharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where CHO Pharma's Debt-to-Asset falls into.

CHO Pharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

CHO Pharma's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(14.311	+	14.589)	/	2881.285
	=	0.01

CHO Pharma's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(14.311	+	14.589)	/	2881.285
	=	0.01

CHO Pharma (ROCO:6586) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

CHO Pharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of CHO Pharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

CHO Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CHO Pharma Inc (ROCO:6586) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3, Park Street, 18F, Building F, Nangang, Taipei, TWN, 11503

Website

http://www.chopharma.com

CHO Pharma Inc is a biopharmaceutical company mainly focused on the development and commercialization of innovative products based on the proprietary glycan engineering technologies. It offers antibodies, such as CHO-H01, CHO-H02, CHO-A04 for cancer; CHO-H03, an antibody for autoimmune disease; CHO-S05 dual-effect anti-flu drugs; and CHO-V06 glycan-based vaccines and drugs.

CHO Pharma Headlines

No Headlines